Publications by authors named "Andrew Zalewski"

Claim this Profile
S
Streamlining cardiovascular clinical trials to improve efficiency and generalisability.
Faiez Zannad, Marc A Pfeffer, Deepak L Bhatt, Denise E Bonds, Jeffrey S Borer, Andrew Zalewski

Heart· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electronic health records to facilitate clinical research.
Martin R Cowie, Juuso I Blomster, Lesley H Curtis, Sylvie Duclaux, Ian Ford, Andrew Zalewski

Clin Res Cardiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.
Neville Jackson, Dan Atar, Maria Borentain, Günter Breithardt, Martin van Eickels, Andrew Zalewski

Eur Heart J· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations.
Muthiah Vaduganathan, Javed Butler, Lothar Roessig, Gregg C Fonarow, Stephen J Greene, Andrew Zalewski

Heart Fail Rev· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.
Mihai Gheorghiade, Muthiah Vaduganathan, Stephen J Greene, Robert J Mentz, Kirkwood F Adams, Andrew Zalewski

Heart Fail Rev· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Anastasia Lesogor, Jay N Cohn, Roberto Latini, Gianni Tognoni, Henry Krum, Andrew Zalewski

Eur J Heart Fail· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
Faiez Zannad, Angeles Alonso Garcia, Stefan D Anker, Paul W Armstrong, Gonzalo Calvo, Andrew Zalewski

Eur J Heart Fail· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardization of outcome measures in clinical trials of pharmacological treatment for abdominal aortic aneurysm.
Xing Li Wang, Matt M Thompson, William P Dole, Ronald L Dalman, Andrew Zalewski

Expert Rev Cardiovasc Ther· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Paul M Ridker, Tom Thuren, Andrew Zalewski, Peter Libby

Am Heart J· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future of clinical trials in secondary prevention after acute coronary syndromes.
Héctor Bueno, Paul W Armstrong, Martin J Buxton, Nicolas Danchin, Jacobus Lubsen, Andrew Zalewski

Eur Heart J· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1).
Joanna J Wykrzykowska, Hector M Garcia-Garcia, Dick Goedhart, Andrew Zalewski, Patrick W Serruys

Int J Cardiol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral artery disease, biomarkers, and darapladib.
Jeffrey S Berger, Christie M Ballantyne, Michael H Davidson, Joel L Johnson, Elizabeth A Tarka, Andrew Zalewski

Am Heart J· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease.
Tjun Y Tang, Simon P S Howarth, Sam R Miller, Martin J Graves, Andrew J Patterson, Andrew Zalewski

J Am Coll Cardiol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Robert E Ratner, Christopher P Cannon, Hertzel C Gerstein, Richard W Nesto, Patrick W Serruys, Andrew Zalewski

Am Heart J· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Robert L Wilensky, Yi Shi, Emile R Mohler, Damir Hamamdzic, Mark E Burgert, Andrew Zalewski

Nat Med· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Patrick W Serruys, Héctor M García-García, Pawel Buszman, Paul Erne, Stefan Verheye, Andrew Zalewski

Circulation· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature.
Emile R Mohler, Lea Sarov-Blat, Yi Shi, Damir Hamamdzic, Andrew Zalewski

Arterioscler Thromb Vasc Biol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Emile R Mohler, Christie M Ballantyne, Michael H Davidson, Markolf Hanefeld, Luis M Ruilope, Andrew Zalewski

J Am Coll Cardiol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
Yi Shi, Ping Zhang, LiFeng Zhang, Hashim Osman, Emile R Mohler, Andrew Zalewski

Atherosclerosis· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lp-PLA2: a new kid on the block.
Andrew Zalewski, Jeanenne J Nelson, Lisa Hegg, Colin Macphee

Clin Chem· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target.
Colin H Macphee, Jeanenne Nelson, Andrew Zalewski

Curr Opin Pharmacol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS).
Carlos A G Van Mieghem, Eugène P McFadden, Pim J de Feyter, Nico Bruining, Johannes A Schaar, Andrew Zalewski

J Am Coll Cardiol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-man prospective evaluation of temporal changes in coronary plaque composition by in vivo intravascular ultrasound radiofrequency data analysis: an Integrated Biomarker and Imaging Study (IBIS) substudy.
Gastón A Rodriguez-Granillo, Patrick W Serruys, Eugène P McFadden, Carlos A G van Mieghem, Dick Goedhart, Andrew Zalewski

EuroIntervention· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology.
Carlos A G Van Mieghem, Nico Bruining, Johannes A Schaar, Eugene McFadden, Nico Mollet, Andrew Zalewski

Int J Cardiovasc Imaging· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.
Colin Macphee, G Martin Benson, Yi Shi, Andrew Zalewski

Expert Opin Investig Drugs· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis